US approves first drug for severe form of fatty liver disease
Washington (AFP) - The US Food and Drug Administration (FDA) on Thursday approved the first medication for people with a severe type of non-alcoholic fatty liver disease. Madrigal Pharmaceuticals' Rezdiffra was shown to improve liver scarring in a clinical trial involving hundreds of people with non-alcoholic steatohepatitis (NASH), the worst form of the condition caused by a buildup of fat in the liver. "Previously, patients with NASH who also have notable liver scarring did not have a medication that could directly address their liver damage," said the FDA's Nikolay Nikolov. "Today's approva...